source
- Sionna Therapeutics reports early-stage cystic fibrosis trial failure, dampening challenge to VertexSionna Therapeutics said its lead cystic fibrosis drug did not meet primary endpoints in an early-stage study, marking a setback for the company. The result reduces expectations that Sionna could…
- Sionna’s Phase 2a CF trial fails, shares plunge as Vertex’s Trikafta remains standard of careSionna Therapeutics announced that its Phase 2a cystic fibrosis trial of the NBD1 stabilizer SION-719 did not meet its primary endpoint, sending the company’s stock down more than 90% in pre‑market…